pla

Lp-PLA2-IN-3 is a potent, orally bioactive lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor, effectively inhibiting recombinant human [Lp-PLA2] with an IC50 value of 14 nM.

Lp-PLA2-IN-2 is a selective and potent lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor, with an IC50 of 120 nM for recombinant human Lp-PLA2.

Lp-PLA2-IN-1 (Lp-PLA2 inhibitor 1) suppresses Lp-PLA2 activity processes for their preparation. Lp-PLA2-IN-1 (Lp-PLA2 inhibitor 1) also inhibits to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example, atherosclerosis, Alzheimer's disease.

Hnps-PLA Inhibitor is an inhibitor of human nonpancreatic secretory Phospholipase A (hnps-PLA).

Ecopladib (PLA 725) is a sub-micromolar inhibitor of cytosolic phospholipase A2α (cPLA2α), with IC50s of 0.15 μM and 0.11 μM in the GLU micelle and rat whole blood assays, respectively.

Giripladib (PLA695)(PLX-695) is a cPLA2-specific inhibitor that inhibits the radiation-induced increase of phosphorylated ERK and phosphorylated Akt in endothelial cells.

Efipladib is a phospholipase inhibitor. Efipladib decreases nociceptive responses without affecting PGE2 levels in the cerebral spinal fluid.

Manassantin A is a high potent HIF-1 inhibitor, it protects the gastric mucosa from ethanol-induced acute gastric injury, and suggest that these protective effects might be associated with COX/PGE2 stimulation, inhibition of iNOS production and NF-κB act

Polylactic acid (PLA) is a biodegradable and biocompatible polymer that is widely used as a carrier in drug delivery systems and as a structural material for tissue engineering and medical implants. It acts as a controlled release matrix through ester bond hydrolysis, gradually releasing encapsulated drugs and metabolizing into non-toxic lactic acid. Polylactic acid possesses adjustable degradation rates, mechanical properties, and the ability to be combined with other polymers, making it suitable for localized or systemic drug delivery, orthopedic fixation devices, and 3D printed scaffolds for bone regeneration.

(2S,3S,4R,2'R)-2-(2'-hydroxytetracosanoylamino)octadecane-1,3,4-triol shows selectively inhibitory activity against phospholipase A 2 (PLA 2) secreted from Crotalus adamenteus venom at concentration of 100 ug/mL.

Variabilin, a novel inhibitor of human platelet aggregation, it is a potent RGD (Arg-Gly-Asp)-containing antagonist of the fibrinogen receptor glycoprotein IIb-IIIa (GPIIb-IIIa; αIIbβ3) and the vitronectin receptor αvβ3.Variabilin is also an antimicrobial furanosesterterpene. Variabilin is an inhibitor of human secretory and cytosolic phospholipase A2 (PLA2) activities that controls eicosanoid production in vitro and in vivo, inhibits neutrophil degranulation and superoxide generation in vitro and shows anti-inflammatory activity after topical or p.o. administration to mice.

PF 5212372 (PLA-950, ZPL-521, ZPL 5212372) is a potent and selective inhibitor of cPLA2.

Lp-PLA2-IN-17 (Compound 39) acts as an inhibitor of Lp-PLA 2. It is utilized in research to explore disorders associated with the hydrolysis of oxidized lipids into two inflammatory substances mediated by Lp-PLA 2 [1].

PLA2-IN-1 (Compound 7) is a potent and selective inhibitor of phospholipase A (PLA2) with an IC50 value of 1 nM. It effectively inhibits PLA2-induced coagulation disorders in vitro and shows potential for use as an antidote for snake bites caused by cobra venom.

Lp-PLA2-IN-11 is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2) with potential applications in diseases associated with Lp-PLA2 activity [e.g., atherosclerosis, Alzheimer's disease].

Lp-PLA2-IN-10 is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2), formerly known as platelet-activating factor acetylhydrolase (PAF-AH). This enzyme catalyzes the hydrolysis of lipoprotein lipids or phospholipids. The compound has research potential in neurodegenerative diseases such as Alzheimer's disease (AD), as well as glaucoma, age-related macular degeneration (AMD), and cardiovascular diseases like atherosclerosis[1].

Lp-PLA2-IN-4 is a potent lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor and an inhibitor of platelet-activating factor acetylhydrolase (PAF-AH), a phospholipase A2 involved in lipoprotein lipid or phospholipid hydrolysis. Lp-PLA2-IN-4 has potential for study in diseases associated with Lp-PLA2 activity, such as Alzheimer's disease and atherosclerosis. [Compound 38]

Lp-PLA2-IN-5 is a potent lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor and an inhibitor of platelet-activating factor acetylhydrolase (PAF-AH), a phospholipase A2 involved in lipoprotein lipid or phospholipid hydrolysis. Lp-PLA2-IN-5 (Compound 35) may have potential applications in studying diseases linked to Lp-PLA2 activity, including Alzheimer's disease and atherosclerosis.

Lp-PLA2-IN-6 is a tetracyclic pyrimidinone compound that is a potent inhibitor of Lp-PLA2 and is able to act on rhLp-PLA2 (pIC50: 10.0). lp-PLA2-IN-6 has shown research potential in neurodegenerative diseases.

Lp-PLA2-IN-9 (compound 17) is a tetracyclic pyrimidinone compound and a potent inhibitor of Lp-PLA2, targeting rhLp-PLA2 with a pIC50 of 10.1, and has demonstrated research potential in neurodegenerative diseases.

Lp-PLA2-IN-13 (compound 15), a potent Lp-PLA2 inhibitor, shows promise for neurodegenerative disease research [1].

Lp-PLA2-IN-14 (Compound 19), an inhibitor of rhLp-PLA2, exhibits a potent inhibitory effect with a pIC50 value of 8.4 and is applicable in research on neurodegenerative disorders including Alzheimer Disease (AD), glaucoma, age-related macular degeneration (AMD), and cardiovascular diseases such as atherosclerosis [1].

Anti-PLA2G1B Antibody is a CHO-expressed humanized antibody targeting PLA2G1B. It features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For isotype control, refer to HumanIgG1kappa, Isotype Control.

Oxaliplatin (L-OHP) is a DNA alkylating agent, an inhibitor of DNA synthesis. Oxaliplatin causes DNA cross-linking damage, preventing DNA replication and transcription and leading to cell death. Oxaliplatin induces autophagy.